Ascendis Pharma A/S
ASND164.150USD
+3.700+2.31%
Close 04/25, 16:00（ET）Quotes delayed by 15 min
9.95BMarket Cap
LossP/E TTM
More Details of Ascendis Pharma A/S Company
Ascendis Pharma A/S is a Denmark-based company that manufactures pharmaceutical products. The Company produces products for the treatments of growth hormone deficiency, endocrinology, central nervous system disorders, infectious diseases, and diabetes. The Company operates globally though its subsidiaries: Ascendis Pharma GmbH (Germany), Ascendis Pharma, Inc. (Delaware, United States), Ascendis Pharma Endocrinology, Inc. (Delaware, United States), Ascendis Pharma, Ophthalmology Division A/S (Denmark), Ascendis Pharma, Endocrinology Division A/S (Denmark), Ascendis Pharma Bone Diseases A/S (Denmark), Ascendis Pharma Growth Disorders A/S (Denmark) and Ascendis Pharma Oncology Division A/S (Denmark).
Company Info
Company codeASND
Company nameAscendis Pharma A/S
IPO dateJan 28, 2015
Founded at2006
CEOMr. Jan Moller Mikkelsen
Number of employees- -
Security typeDepository Receipt
Fiscal year-endJan 28
AddressTuborg Boulevard 12
CityHELLERUP
Stock exchangeNASDAQ Global Select Consolidated
CountryDenmark
Postal code2900
Phone4570222244
Websitehttps://ascendispharma.dk/
Company codeASND
IPO dateJan 28, 2015
Founded at2006
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Michael Wolff Jensen
Mr. Michael Wolff Jensen
Executive Vice President, Chief Legal Officer, Member of the Executive Board
Executive Vice President, Chief Legal Officer, Member of the Executive Board
5.76K
+198.45%
Mr. Flemming Steen Jensen
Mr. Flemming Steen Jensen
Executive Vice President, Product Supply and Quality
Executive Vice President, Product Supply and Quality
1.86K
+100.43%
Mr. Lars Holtug, CPA
Mr. Lars Holtug, CPA
Independent Director
Independent Director
1.59K
+78.59%
Ms. Lisa Bright
Ms. Lisa Bright
Independent Director
Independent Director
1.09K
+178.01%
Dr. Albert Cha, M.D., Ph.D.
Dr. Albert Cha, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.09K
+178.01%
Ms. Siham Imani
Ms. Siham Imani
Independent Director
Independent Director
364.00
--
Mr. Mads Bodenhoff
Mr. Mads Bodenhoff
Senior Vice President, Head of Finance and Principal Accounting Officer
Senior Vice President, Head of Finance and Principal Accounting Officer
193.00
--
Mr. Donovan (Jay) Wu
Mr. Donovan (Jay) Wu
Executive Vice President, U.S. President
Executive Vice President, U.S. President
--
--
Dr. Aimee Shu,, M.D.
Dr. Aimee Shu,, M.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
--
--
Mr. William Carl (Bill) Fairey, Jr.
Mr. William Carl (Bill) Fairey, Jr.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Michael Wolff Jensen
Mr. Michael Wolff Jensen
Executive Vice President, Chief Legal Officer, Member of the Executive Board
Executive Vice President, Chief Legal Officer, Member of the Executive Board
5.76K
+198.45%
Mr. Flemming Steen Jensen
Mr. Flemming Steen Jensen
Executive Vice President, Product Supply and Quality
Executive Vice President, Product Supply and Quality
1.86K
+100.43%
Mr. Lars Holtug, CPA
Mr. Lars Holtug, CPA
Independent Director
Independent Director
1.59K
+78.59%
Ms. Lisa Bright
Ms. Lisa Bright
Independent Director
Independent Director
1.09K
+178.01%
Dr. Albert Cha, M.D., Ph.D.
Dr. Albert Cha, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.09K
+178.01%
Ms. Siham Imani
Ms. Siham Imani
Independent Director
Independent Director
364.00
--
Revenue Breakdown
Currency: EURUpdate time: Sun, Apr 6
Currency: EURUpdate time: Sun, Apr 6
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessEUR
Name
Revenue
Proportion
Commercial sale of products
55.71M
96.33%
Rendering of services
1.27M
2.20%
License
851.00K
1.47%
Sale of clinical supply
0.00
0.00%
By RegionEUR
Name
Revenue
Proportion
North America
48.76M
84.31%
Europe
8.15M
14.09%
Asia
924.00K
1.60%
Rest of world
924.00K
1.60%
By Business
By Region
By BusinessEUR
Name
Revenue
Proportion
Commercial sale of products
55.71M
96.33%
Rendering of services
1.27M
2.20%
License
851.00K
1.47%
Sale of clinical supply
0.00
0.00%
Shareholder
Update time: Sat, Apr 26
Update time: Sat, Apr 26
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
RA Capital Management, LP
16.66%
Westfield Capital Management Company, L.P.
9.11%
Avoro Capital Advisors LLC
8.41%
Artisan Partners Limited Partnership
7.33%
Janus Henderson Investors
7.22%
Other
51.27%
Shareholder Statistics
Shareholder
Proportion
RA Capital Management, LP
16.66%
Westfield Capital Management Company, L.P.
9.11%
Avoro Capital Advisors LLC
8.41%
Artisan Partners Limited Partnership
7.33%
Janus Henderson Investors
7.22%
Other
51.27%
Type
Shareholder
Proportion
Investment Advisor/Hedge Fund
42.21%
Investment Advisor
39.31%
Hedge Fund
25.01%
Research Firm
2.54%
Individual Investor
0.78%
Family Office
0.44%
Family Office
0.44%
Family Office
0.44%
Venture Capital
0.38%
Institutional Shareholding
Update time: Mon, Jan 20
Update time: Mon, Jan 20
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
473
67.43M
111.11%
-2.45M
2024Q4
488
67.37M
111.00%
-7.76M
2024Q3
475
65.25M
107.66%
-6.23M
2024Q2
459
63.44M
108.94%
-9.21M
2024Q1
453
63.54M
109.13%
-8.68M
2023Q4
430
62.90M
109.00%
-9.55M
2023Q3
414
62.85M
109.61%
-11.90M
2023Q2
426
63.03M
109.93%
-13.27M
2023Q1
427
63.10M
110.08%
-9.14M
2022Q4
426
67.66M
118.40%
-4.66M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
RA Capital Management, LP
10.11M
16.66%
+402.32K
+4.14%
Dec 31, 2024
Westfield Capital Management Company, L.P.
5.53M
9.11%
+394.47K
+7.68%
Dec 31, 2024
Avoro Capital Advisors LLC
5.10M
8.41%
+114.17K
+2.29%
Dec 31, 2024
Artisan Partners Limited Partnership
4.45M
7.33%
+39.31K
+0.89%
Dec 31, 2024
Janus Henderson Investors
4.38M
7.22%
+193.69K
+4.63%
Dec 31, 2024
Fidelity Management & Research Company LLC
4.36M
7.18%
-196.51K
-4.32%
Dec 31, 2024
Capital International Investors
2.86M
4.72%
+753.86K
+35.74%
Dec 31, 2024
T. Rowe Price Investment Management, Inc.
2.73M
4.49%
+960.50K
+54.42%
Dec 31, 2024
T. Rowe Price Associates, Inc.
2.28M
3.76%
+162.08K
+7.64%
Dec 31, 2024
MFS Investment Management
1.86M
3.07%
-415.00
-0.02%
Dec 31, 2024
View more
Related ETFs
Update time: Sun, Apr 6
Update time: Sun, Apr 6
Name
Proportion
Harbor Health Care ETF
16.1%
Virtus LifeSci Biotech Products ETF
1.93%
BNY Mellon Innovators ETF
1.85%
Tema Cardiovascular and Metabolic ETF
1.43%
American Century Focused Dynamic Growth ETF
1.43%
ProShares Ultra Nasdaq Biotechnology
0.94%
Invesco Nasdaq Biotechnology ETF
0.9%
JPMorgan Healthcare Leaders ETF
0.66%
iShares Biotechnology ETF
0.61%
Main Thematic Innovation ETF
0.61%
View more
Harbor Health Care ETF
Proportion16.1%
Virtus LifeSci Biotech Products ETF
Proportion1.93%
BNY Mellon Innovators ETF
Proportion1.85%
Tema Cardiovascular and Metabolic ETF
Proportion1.43%
American Century Focused Dynamic Growth ETF
Proportion1.43%
ProShares Ultra Nasdaq Biotechnology
Proportion0.94%
Invesco Nasdaq Biotechnology ETF
Proportion0.9%
JPMorgan Healthcare Leaders ETF
Proportion0.66%
iShares Biotechnology ETF
Proportion0.61%
Main Thematic Innovation ETF
Proportion0.61%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data